Mast cells (MCs) are critical components of the innate immune system and important for host defense, allergy, autoimmunity, tissue regeneration and tumor progression. Dysregulated MC development leads to systemic mastocytosis (SM), a clinically variable but often devastating family of hematologic disorders. Here we report that induced expression of Lin28, a heterochronic gene and pluripotency factor implicated in driving a fetal hematopoietic program, caused MC accumulation in adult mice in target organs such as the skin and peritoneal cavity. In vitro assays revealed a skewing of myeloid commitment in LIN28B-expressing hematopoietic progenitors, with increased levels of LIN28B in common myeloid and basophil-MC progenitors altering gene expression patterns to favor cell fate choices that enhanced MC specification. In addition, LIN28B-induced MCs appeared phenotypically and functionally immature, and in vitro assays suggested a slowing of MC terminal differentiation in the context of LIN28B upregulation. Finally, interrogation of human MC leukemia samples revealed upregulation of LIN28B in abnormal MCs from patients with SM. This work identifies Lin28 as a novel regulator of innate immune function and a new protein of interest in MC disease.
INTRODUCTION
Mast cells (MCs) are key effectors in allergic responses, expressing (along with basophils) the high-affinity receptor for immunoglobulin E (IgE; FcεRI). Crosslinking FcεRI on tissue MCs initiates the immediate hypersensitivity reaction, with local release of histamine and inflammatory cytokines. This supports innate immune defense against infections and has an important role in autoimmunity. [1] [2] [3] [4] Aside from their central role in allergy and inflammation, it is increasingly clear that MCs play a pivotal role in tissue regeneration and tumor remodeling. [5] [6] [7] [8] [9] Dysregulated MC development and activation leads to mastocytosis, a poorly understood group of myeloproliferative neoplasms characterized by abnormal growth and activation of immature MCs and their precursors. The WHO recently classified mastocytosis into seven variants, [1] [2] [3] [4] 10 ranging from cutaneous mastocytosis to MC leukemia (MCL). These are highly clinically variable, with median survival rates of 2 months for MCL 11, 12 but virtually no mortality for mild forms. Mastocytosis is characterized by upregulated c-Kit signaling 13 and the vast majority of systemic mastocytoses harbor an imatinib-insensitive activating c-Kit mutation (usually D816V), [14] [15] [16] [17] but this cannot explain the wide clinical variability. Understanding normal MC development and its dysregulation in systemic mastocytosis (SM) is of central importance to developing new therapies for these disorders.
In contrast to other myeloid lineages, relatively little is known about MC development, in part because MCs are rare and difficult to isolate. Developing MC precursors (MCPs) circulate through the bloodstream and only complete differentiation after migrating into skin, heart, lung and other target organs. [18] [19] [20] MCPs arise from lineage-negative (Lin − ) c-kit + Sca-1 − myeloid progenitors (MPs) in the bone marrow (BM), although there is controversy regarding their specific lineal relationship with other myeloid precursors. 18, 21, 22 MC development and differentiation is influenced by the balance between core myeloid transcription factors such as C/EBPα, MITF, GATA-1, PU.1 and GATA-2, and responsive to signals elaborated by PLA2G4 and PI-3K. 19, [23] [24] [25] [26] During maturation, MCs upregulate c-kit and FcεRIα and induce expression of neutral granule components such as carboxypeptidase A3, chymase, cathepsin G, granzyme B and the tryptases. 2 The heterochronic RNA-binding factor Lin28 is highly expressed in embryonal tissues [27] [28] [29] and, along with Oct4, Sox2 and Nanog, reprograms somatic fibroblasts into pluripotent stem cells. 30 Lin28 has been heavily studied in tumorigenesis, 28, 29, [31] [32] [33] [34] and has been implicated in obesity, 35 metabolism 36 and tissue regeneration. 37 Mammals express two isoforms of Lin28 (a and b). Both proteins can enforce proliferative programs and oppose cellular differentiation, and can have similar physiological functions, although it is clear that each protein has unique properties as well (reviewed in ref. 27) . Although the canonical downstream effect of both isoforms is to inhibit biogenesis of the let-7 family of microRNAs, other functions have also been ascribed to these proteins. 38, 39 Recent studies have begun to examine the role of LIN28B, in particular, in hematopoiesis, [40] [41] [42] [43] and indicate that reactivation of LIN28B in adult blood cells can revert their phenotypes to an immature stage and upregulate a fetal hematopoietic program resulting in fetal globin expression and increased production of 'primitive' γδ T and B-1 B cells. A physiologic role for LIN28B in hematopoietic development remains uncertain; knockout model development is challenged by redundancies in the Lin28 isoforms and the essential role of these genes in embryonal development.
The role of Lin28 in solid tumors is well documented, 28,29,32-34 but its association with hematologic malignancy is largely undefined. Some reports suggest that LIN28B overexpression can result in lymphoid malignancy, 44, 45 whereas other studies have not supported a role for Lin28 in hematologic malignancy. 43, 46 We show here that expression of LIN28B in adult mice drives accumulation of immature MCs, resulting in an overabundance of immature MCs that are hypofunctional upon antigen challenge in vivo. We further demonstrate that LIN28B acts at multiple stages of MC development, both to favor MC fate choice and to impair terminal differentiation. Finally, we find that LIN28B is highly overexpressed in abnormal MCs from patients with systemic mastocytosis (SM); this and the proliferation of immature MCs characteristic of SM mirror our animal model findings. Together, these data implicate aberrant Lin28 expression in MC disease and dysfunction.
MATERIALS AND METHODS
iLIN28B and ilet7 mice iLIN28B and ilet7 mice have been described 36 and were maintained on a C57BL/6 background. LIN28B or let-7 transgenes were induced with 1 mg/ml of doxycycline in drinking water for 2 weeks. Unless otherwise stated, mice were 6-12 weeks old at induction. BM transplant recipients were induced for 2 weeks after 16-20 weeks of post-transplant recovery. All control mice were age-and gender-matched.
Flow cytometric analysis
Mononuclear cells harvested from hematopoietic tissues, peritoneal lavage, in vitro cell culture or methylcellulose were stained with directly conjugated antibodies or with biotinylated antibodies followed by fluorophore-conjugated streptavidin, then analyzed by flow cytometry on a BD LSRII or BD AriaII (Becton Dickinson, East Rutherford, NJ, USA). Data were analyzed using FlowJo (Treestar Industries, Ashland, OR, USA). Antibodies are listed in Supplemental Methods.
In vitro methylcellulose cultures
Flourescence-associated cell sorted progenitors were plated in Methocult m3434 (Stem Cell Technologies, Vancouver, BC, USA) at 100-1000 cells/ 1.5 ml/3 cm dish and cultured for 10 days. Colonies were counted and morphologically categorized as CFU-G, CFU-M, CFU-GM, CFU-GEMM or CFU-E/BFU-E before harvest for further analysis.
BM-derived MC cultures
BM was isolated from uninduced C57BL/6, iLIN28B and ilet7 mice and cultured in Iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum, 50 ng/ml recombinant murine stem cell factor and 10 ng/ml recombinant mouse interleukin-3 (R&D Systems, Minneapolis, MN, USA). Cultures were induced with 1 μg/ml doxycycline. After 5 weeks, 495% of suspended cells from wild-type mice displayed MC morphology and granulation and were toluidine blue-positive and c-kit hi FcεRIα hi by flow cytometry.
Histologic evaluation
Cytospins were prepared using mononuclear cell suspensions derived from hematopoietic tissues or in vitro cell culture on a Shandon Cytospin 2 (Thermo Fisher Scientific, Waltham, MA, USA) and stained with Wright-Giemsa (Sigma-Aldrich, St Louis, MO, USA). Peripheral blood smears were hand drawn on glass slides and stained with Wright-Giemsa. MCs were stained with acid toluidine blue solution after fixation in Mota's solution. Tissues were fixed in neutral-buffered formalin and processed by the DF/ HCC Specialized Histopathology facility.
Electron microscopy
Cell pellets were fixed in 2.5% glutaraldehyde, 1.25% paraformaldehyde and 0.03% picric acid in 0.1 M sodium cacodylate (pH 7.4). Subsequent preparation and electron microscopy were performed at the electron microscopy Core Facility at Harvard Medical School.
BM transplantation
Mononuclear cells were harvested from the BM of age-and gendermatched male or female mice and either directly retroorbitally injected (1 × 10 6 cells/recipient) or stained using SLAM markers, flourescenceassociated cell sorting for long-term HSCs (Lin − Sca-1 + c-Kit + CD150 + CD48 -), and then injected into anesthetized, lethally irradiated (950 rad) congenic (CD45.1 + ) recipients, either with competitor CD45.1 + BM cells or with 3x10 5 CD45.1 + helper cells to avoid radiation-induced hematologic failure.
Passive cutaneous anaphylaxis assay
Passive cutaneous anaphylaxis assays were performed according to standard protocols. 47 Briefly, control and iLIN28B mice were induced for 2 weeks and then ear pinnae were injected with phosphate-buffered saline (control) or anti-dinitrophenol IgE. 24 h later, mice were tail-vein injected with dinitrophenol-human serum albumin in a solution of Evans blue dye; histamine release resulted in increased vascular permeability and dye extravasation into the ear pinna. Pinnae were removed, macerated and incubated overnight in acetone or formamide. After incubation, 570 nm absorbance of the supernatant was spectrophotometrically measured. Positive control pinnae were injected directly with histamine followed by dinitrophenol-human serum albumin in Evans blue dye.
Real-time PCR
RNA extraction from Trizol and real-time PCR were carried out according to manufacturer's instructions (Life Technologies, Carlsbad, CA, USA). Banked patient samples were obtained through Dana-Farber Cancer Institute (DFCI) IRB protocol 01-206 (R Soiffer, PI). BM aspirates were centrifuged for buffy coat isolation, then subjected to dextran erythrocyte sedimentation followed by lysis in ammonium-chloridepotassium buffer. Subsequently, BM mononuclear cells were stained with antibodies to c-Kit, CD25, CD2 and CD45; abnormal MCs (as defined in the patients' medical records) and control cells were flourescence-activated cell sorted into Trizol for further analysis. Primer sequences are provided in Supplemental Methods. Values are expressed as fold-change overexpression in fetal liver, which has been shown to express high levels of Lin28b. P = 0.0005 by one-way analysis of variance in both cases.
RESULTS

Lin28b is normally downregulated upon MC differentiation in adult mice
Recent analyses have implicated Lin28b in the specification of primitive hematopoietic lineages during fetal development, and shown that it is highly expressed in mouse fetal liver but that expression declines during postnatal life 42 (https://gexc.stanford. edu/search). To evaluate the possible involvement of Lin28b in postnatal MC development, we first examined Lin28b expression during MC differentiation in BM-derived MC cultures (BMMCs). MC development is poorly understood, and its kinetics are difficult to study in vivo; the BMMC system represents a very useful and wellaccepted model system for the analysis of MC development and function. 48 In addition, BMMCs permit the synchronous generation of large numbers of MCs, enabling kinetic evaluation of MC development. Lin28b transcription decreased over time in BMMC culture ( Figure 1 ), indicating that changes in Lin28 levels may be important for MC maturation.
Expression of LIN28B leads to increased numbers of MCs and their progenitors
To study further the role of Lin28b in MC development, we used inducible transgenic mice that express LIN28B upon doxycycline treatment (iLIN28B mice 36 ). After a 2-week induction (Figure 2a ), hematopoietic cells were harvested from spleen, BM, peritoneal cavity and peripheral blood and analyzed by histology and flow cytometry. LIN28B-expressing mice harbored greater numbers of peritoneal MCs, identified as c-kit + FcεRIα + , than age-and gendermatched controls (5.22 ± 0.287% of live peritoneal cavity cells in iLIN28B mice (n = 12) versus 2.98 ± 0.202% in control C57BL/6 mice (n = 7; Figure 2b ). Sectioning and staining of ear pinnae revealed a similar (~1.5-fold) increase in MCs in the skin of induced iLIN28B (b) Induction of LIN28B leads to a 1.75-fold increase in peritoneal mast cells. Peritoneal lavage mononuclear cells were stained with antibodies to c-Kit and FcεRIα and analyzed by flow cytometry (left) or cytospun and stained with toluidine blue (right). Images were obtained on an Olympus BX60 light microscope equipped with an Olympus DP70 camera using Olympus DP Controller software; original magnification × 600 for all images. (c) iLIN28B mice have higher numbers of skin-resident mast cells than controls after induction. Ear sections were obtained and stained with toluidine blue (left) and toluidine blue (+) mast cells per high-powered field (hpf ) were enumerated (right). Images were obtained on an Olympus BX60 light microscope equipped with an Olympus DP70 camera using Olympus DP Controller software; original magnification × 600 for all images. (d, e) LIN28B expression results in increases in splenic (d) and bone marrow (e) mast cell precursors (MCPs). Spleens from induced iLIN28B (circles) and control mice (squares) were harvested, processed and stained for lineage markers, c-Kit, integrinβ7 and F c γRII/III; splenic mast cell precursors are lin − c-Kit + F c γRII/III + intβ7 + . Bone marrow mononuclear cells were stained for lineage markers, Sca-1, c-Kit, CD150, Flk2, integrinβ7 and CD27. BMMCPs are lin − Sca-1 − c-Kit + CD150 -Flk2 -intβ7 + CD27 + . mice as assessed by toluidine blue staining (Figure 2c , arrow heads). iLIN28B mice also had a 3.6-fold increase in splenic MCPs (Figure 2d , 0.055 ± 0.006% of live cells in iLIN28B (n = 12) vs 0.015 ± 0.002% in controls (n = 7)) and twice as many BM MCPs (Figure 2e , 0.122 ± 0.009% of live cells in iLIN28B mice vs 0.064 ± 0.005% in controls, n = 9 of each genotype) as controls. MCPs were defined as lin − c-Kit + F c γRII/III + intβ7 + in the spleen and lin − Sca-1 − c-Kit + CD150 -Flk2 -intβ7 + CD27 dim in the BM. 18, 20 Lin28 expression promotes MCP accumulation To understand how Lin28 expression augments MC numbers, we next examined MC developmental stages in iLIN28B mice. MC provenance is not completely understood, and MCs appear capable of developing from several different progenitors. [18] [19] [20] [21] 49 However, the most exhaustive studies indicate that MCs develop predominantly from the megakaryocyte-erythroid progenitor (MEP) pool of MPs. 18, 20 Interestingly, induction of LIN28B caused skewing of the MP compartment in the marrow of iLIN28B mice, with significantly higher percentages of MEPs than in controls ( Figure 3 ). This increase in MEPs was accompanied by decreases in the proportions of MPs that were granulocyte-macrophage precursors (Figure 3 ), although the percentage of live cells that were granulocyte-macrophage precursors was less affected. There were no statistically significant differences in the proportions of cells in the common MP (CMP) pool, suggesting that Lin28 may act at the level of CMP fate choice. In keeping with these findings, mice induced to express let-7 for 2 weeks were found to have fewer numbers of BM MCPs compared with controls ( Supplementary Figure S1 , 0.01 ± 0.003 vs 0.048 ± 0.007%, P = 0.007). Because the lifespan of fully differentiated MCs exceeds the 2 week induction period used, 50,51 we did not expect to see differences in the frequencies of peritoneal MCs. However, a trend toward reduced peritoneal MC numbers was observed (1.88 ± 0.3 vs 2.39 ± 0.02% of live cells; P = 0.16; Supplementary Figure S1 ). Taken together, these data indicate that Lin28b expression acts to promote MC lineage commitment at the CMP → MEP transition.
The MC phenotype in iLIN28B mice is intrinsic to hematopoietic cells To determine whether the effects of LIN28B expression on MC development in iLIN28B mice were driven by LIN28B expression in MC precursors themselves, we sorted Lin − Sca-1 + c-kit + progenitor cells from induced iLIN28B BM and cultured them in methylcellulose media containing doxycycline and cytokines that support unbiased myeloid differentiation (m3434, Stem Cell Technologies). After 10 days, Lin − Sca-1 + c-kit + progenitor cells from iLIN28B mice that differentiated in culture generated predominantly c-Kit + F-cεRI lo MCPs (Supplementary Figure S2) , whereas control Lin − Sca-1 + c-kit + progenitors produced a variety of different myeloid cell types. This result indicates that the MC-promoting effects of LIN28B induction in vivo are maintained ex vivo in differentiating hematopoietic progenitors and suggests that LIN28B induction may delay or impair MC terminal differentiation in a cell autonomous manner. However, because the cells assayed in these cultures were harvested from mice in which LIN28B had already been induced in vivo, it remained possible that durable cell-extrinsic effects of prior induction were carried forward into the in vitro setting. Thus, we performed a further, definitive in vivo experiment by analyzing iLIN28B hematopoietic chimeras generated by the transplantation of BM from uninduced LIN28Btransgenic mice into lethally irradiated CD45.1 congenic recipients. After full hematopoietic reconstitution (16-24 weeks), recipient mice were induced to express LIN28B for 2 weeks and analyzed for MC phenotypes. We again found increased numbers of MCPs in the spleen (0.05 ± 0.005% of live splenocytes in iLIN28B chimeras vs 0.03 ± 0.005% in controls, n = 10 in each group) and BM of iLIN28B chimeric mice (0.15 ± 0.008% of live marrow mononuclear cells in iLIN28B chimeras vs 0.07 ± 0.007% in controls, n = 10 in each group; Figures 4b and c). These results mirror those obtained in induced, transgenic iLIN28B mice (Figures 2d and e ).
MCs are long lived, 50, 51 and recipient peritoneal MCs persisted in situ in hematopoietic chimeras, preventing donor reconstitution in the peritoneum. Therefore, another transplantation experiment was performed using recipients that were injected intraperitoneally with distilled water at the time of LIN28B induction to lyse resident recipient MCs. 50 Increased numbers of donor MCs were found in the peritoneal lavage of recipients receiving iLIN28B BM as compared with control marrow (4.94 ± 0.66% of live peritoneal mononuclear cells in iLIN28B chimeras vs 2.49 ± 0.48% in controls, n = 5 for each group, Figure 4d ). These findings, taken together, indicate that the effects of LIN28B in promoting MC fate choice are intrinsic to the hematopoietic compartment.
Expression of LIN28B impedes terminal MC differentiation
To investigate further the finding that LIN28B-induced Lin − Sca-1 + c-kit + progenitor cells are impaired in their ability to differentiate fully into MCs in methylcellulose culture, we studied the kinetics of c-kit and FcεRIα receptor expression, as well as transcriptional and ultrastructural features of developing MCs in iLIN28B and control BMMC cultures. These experiments corroborated our methylcellulose culture studies and demonstrated that, in vitro, LIN28Bexpressing BMMCs matured with delayed kinetics relative to control BMMCs (Figure 5a ). Concordantly, acquisition of toluidine blue staining in cultured cells (Figure 5b ) was delayed. Furthermore, electron microscopy demonstrated a decrease in the number of mature, electron-dense granules in LIN28B-expressing BMMCs (Figures 5c and d, 7 .8 ± 1.06 vs 16.83 ± 1.62 per cell at d32 of culture, n = 25 cells, representative of BMMCs from three different mice per condition), reminiscent of features reported in fetal liver-derived MCs and in human MC disease. 52, 53 Thus, these data suggest that induced LIN28B expression prevents MCs from fully maturing. Figure 4 . The effects of LIN28B overexpression on mast cell development are cell intrinsic. (a) Long-term HSCs (Lin − Sca-1 + c-Kit + CD150 + CD48 − ) were sorted from uninduced iLIN28B (circles) and control mice (squares) and transplanted into lethally irradiated congenic (CD45.1) recipients. After long-term hematopoietic reconstitution, recipients were induced for 2 weeks with 1 g/l doxycycline drinking water and then sacrificed. (b, c) Restriction of LIN28B overexpression to the hematopoietic compartment results in an accumulation of bone marrow and splenic mast cell progenitors very similar to that seen in induced iLIN28B mice. As in Figure 2 , splenic mast cell precursors are lin − c-Kit + F c γRII/III + intβ7 + . BMMCPs are lin − Sca-1 − c-Kit + CD150 -Flk2 − intβ7 + CD27 + . Because peritoneal mast cells are long lived, the majority of MC recovered from the peritoneum were of recipient origin (that is, CD45.1 + ). Thus, the transplant experiment was repeated (d) and distilled water was intraperitoneally injected at the time of induction to lyse resident recipient mast cells. After 2 weeks of induction, iLIN28B overexpression resulted in an increase in peritoneal mast percentages. Cultures were initiated from uninduced control or iLIN28B mice, as described, with or without subsequent induction, and samples were taken at defined timepoints for flow cytometric analysis. Plots represent a time course of maturation; each condition was performed in biological triplicate. These data are summarized in graphical format, showing a clear shift to the right of the immunophenotypic maturation curve of induced iLIN28B BMMC (P = 0.005 by one-way ANOVA). (b) LIN28B overexpression slows acquisition of toluidine blue-positive mast cell granules. Cells were taken from BMMC cultures at the indicated timepoints and cytospun, then stained with Wright-Giemsa preparation (left) or toluidine blue (right). Although iLIN28B cultures did acquire toluidine blue positivity (far right), it occurred with kinetics similar to those seen in a. Images were obtained on an Olympus BX60 light microscope equipped with an Olympus DP70 camera using Olympus DP Controller software; original magnification × 600 for all images. (c) Electron microscopy demonstrates that iLIN28B BMMCs have fewer dense granules than controls. BMMCs at the specified timepoints were visualized by transmission EM and their electron-dense granules enumerated by visual inspection. Differences in total granule number did not reach statistical significance whereas differences in dense granule number were highly statistically significant (d), whether expressed as number of dense granules per cell or percentage of granules that were dense per cell (not shown). Images were acquired on a Philips/FEI Tecnai 12 Biotwin/Spirit TEM equipped with an AMT XR60 camera; original magnification × 2000 for all images. iLIN28B MCs are hypofunctional Delayed kinetics of LIN28B-expressing MC development were not apparent in vivo, although increased numbers of MCPs are consistent with slowed maturation. In vivo development is likely too asynchronous to permit kinetic analyses, particularly as in vitro iLIN28B BMMCs ultimately attained the same immunophenotypic end point as controls (Figure 5a ). To evaluate MC differentiation in vivo, we hypothesized that differences in developmental kinetics might have functional manifestations. To test this, we examined MC histamine release in end organs by performing passive cutaneous anaphylaxis assays. Recipient tissue MCs persist through BM transplant, precluding performance of these assays in transplant recipients. Therefore, we analyzed MC function in iLIN28B transgenic mice. The histamine response to a MC-specific IgE-mediated stimulus was attenuated in iLIN28B mice relative to controls (Figure 6a ). Histamine treatment per se caused equivalent increases in vascular permeability in control and iLIN28B mice (Supplementary Figure S3) , indicating that the diminished extravasation seen in response to MC-specific stimuli was not attributable to an inability of iLIN28B vasculature to respond to histamine. Thus, LIN28B-expressing MCs exhibit an impaired response to IgE signaling in vivo, consistent with a failure to HMGA2 expression mature fully. To test this further, we interrogated MC cytokine responses to IgE-mediated receptor stimulation in BMMC cultures from control and iLIN28B mice that were induced to express LIN28B in vitro at the initiation of the cultures, but not before. iLIN28B BMMCs produced less tumor necrosis factor-α and interleukin-6 in response to FcεRIα stimulation than controls (Figure 6b ), confirming that iLIN28B MCs are intrinsically hypofunctional.
LIN28B downregulates C/ebpa expression To investigate the transcriptional program underlying the production of immature MCs in LIN28B-expressing MC precursors, we performed real-time PCR analysis of RNA isolated from BMMCs of induced or uninduced iLIN28B mice to evaluate genes important in MC development and function. We confirmed that iLIN28B BMMCs expressed high levels of LIN28B and low levels of let-7 species (Figure 7a) , consistent with increased LIN28B activity. Transcription of the let-7 target, Hmga2, was not significantly elevated (Figure 7b ), which may explain why induced iLIN28B animals do not develop MC malignancies (see below). The let-7 target, Igfbp2, was not expressed in BMMCs, with or without LIN28B induction (not shown). However, iLIN28B BMMCs expressed less Fcer1a as determined by flow cytometry (Figure 7b ). Additionally, although expression of MC genes such as Kit and Gata-1 was not substantially altered, LIN28B-expressing BMMC cultures had significantly decreased expression of C/ebpa (0.23 ± 0.07 relative to controls; Figure 7b ). C/ebpα is a key regulator of granulocyte differentiation, 54, 55 and especially of basophil differentiation. 25 Previous studies have demonstrated that fate specification at the level of the basophil-MCP is dictated by the balance between C/ebpα and MITF, with C/ebpα specifying basophil fate. 25 Thus, downregulation of C/ebpα in iLIN28B BMMCs would be expected to favor MC fate choice. Expression of Mitf was also decreased (0.63 ± 0.07-fold relative to controls; Figure 7b ), although to a lesser extent than the decrease in C/ebpa. Thus, expression of LIN28B results in downregulation of genes critical for terminal differentiation of basophils and MCs, with preferential downregulation of the basophil-specification branch of that program. These molecular alterations likely underlie the accumulation of immature MCs seen in iLIN28B mice.
We also performed transcriptional analysis on MPs from iLIN28B mice. Adult MPs represent an earlier stage of development than the cultured BMMCs, and do not express Lin28b at appreciable levels (not shown, but concordant with published datasets at https://gexc.stanford.edu/search and http://www.immgen.org/ databrowser/index.html). Enforced expression of LIN28B in CMPs resulted in transcriptional changes distinct from those seen in BMMCs. Although Fcer1a expression was low in iLIN28B CMPs just as in iLIN28B BMMCs, C/ebpa levels in CMPs were comparable to controls. Furthermore, Gata-1 expression was higher in iLIN28B CMPs than in controls (Figure 7c ). Gata-1, a master regulator of erythropoiesis, is also critical for differentiation of the megakaryocyte, eosinophil and MC lineages, 24 and ectopic expression of Gata-1 converts lymphoid and myelomonocytic precursors into megakaryocyte/erythroid precursors. 56 These findings indicate that induced LIN28B in MCPs augments MC production through distinct mechanisms acting at different stages of development: first, it promotes CMP differentiation to form MEP over granulocyte-macrophage precursor by upregulating Gata-1; and second, it slows terminal differentiation while favoring MC fate choice at the basophil-MCP level by downregulating C/ebpa more than Mitf.
Human SM overexpresses LIN28 Lin28 has been implicated in tumorigenesis, 28, 29, [31] [32] [33] and the accumulation of immature MCs in animals induced to express LIN28B suggested a potential role for this protein in MC disease. We therefore analyzed dysplastic MCs from patients with SM/MCL treated at the DFCI. SM is rare, and patients often have a low disease burden in comparison with other hematologic malignancies. 10, 15 Additionally, dysplastic MCs are difficult to dislodge from the BM, such that aspirates frequently contain very few (o 10%) abnormal MCs. 57 Between 2010 and 2014, 19 patients with SM/MCL were enrolled in the DFCI hematologic malignancy registry. We were able to obtain primary samples from four of these patients, two of whom were treated with midostaurin, a tyrosine kinase inhibitor with multiple targets including c-Kit (Table 1) . 58, 59 BM mononuclear cells from these patients were stained with antibodies for abnormal MC markers previously identified by clinical flow cytometry, including c-Kit, CD45, CD25 and CD2. Cells were sorted and analyzed by real-time PCR for LIN28B expression. Interestingly, and in contrast to the iLIN28B animal model, LIN28B and HMGA2 were both found to be highly expressed (Figure 7d ) in abnormal human MCs as compared with their corresponding nondysplastic BM cells, regardless of clinical subtype or c-Kit mutational status. These results implicate LIN28 as an important cofactor in the pathogenesis of human SM/MCL.
DISCUSSION
Growing evidence highlights the central role of MCs in innate immunity. MCs mediate inflammatory responses in multiple contexts and also coordinate the responses of other immune cells. [1] [2] [3] In rare instances, MC development is subverted to cause mastocytosis or MCL, usually as a result of a somatically acquired c-Kit mutation. 14, 58 However, a subset of pediatric and aggressive MC dyscrasias do not have c-Kit mutations, and MCL often loses c-Kit mutations. 15, 60 Here, we ascribe an important function to the RNA-binding protein Lin28 in MC development and associate upregulation of this protein with aggressive MC malignancy. Lin28 has been extensively studied as a pluripotency and proliferation factor that impairs cellular differentiation. 28, 30 We demonstrate here that enforced expression of LIN28B causes accumulation of MCPs in BM as well as increased MC numbers in end organs. However, the MCs found in iLIN28 tissues are immature in both immunophenotype (FcεRIα lo , c-Kit hi ) and function. Our in vitro studies confirm that Lin28 is normally downregulated during MC development, and reveal that LIN28B induction impedes MC development and results in diminished responses to prototypical MC stimuli. iLIN28B mice also exhibit alterations in cell fate decisions at the CMP and basophil-MCP stage, associated with deregulated expression of transcription factors involved in MC specification and differentiation. It is likely that the accumulation of MCPs in vivo in iLIN28B mice reflects both a slowing in terminal differentiation of these cells and a skewing of cell fate decisions by progenitor cells in the myeloid lineage. It is also possible that LIN28B expression affects MCP compartmentalization or recruitment and/or mature MC proliferation, and that these mechanisms augment the developmental effects of LIN28B to cause accumulation of MCPs in vivo.
Lin28 activity impacts a number of biological processes. The best characterized of these is its inhibition of the biogenesis of the microRNA let-7, although let-7 independent functions of Lin28 have been described. 38, 39 In MC development, enforced expression of let-7 yields an opposite phenotype to that of Lin28 expression, suggesting that the effects of LIN28B in this system may be mediated in part through let-7 (Supplementary Figure S2) . However, although expression of LIN28B results in marked suppression of let-7 (Figure 7a ), canonical downstream targets such as Hmga2 are not uniformly upregulated. This finding suggests a context-dependency to Lin28b expression, as well as let-7 independent mechanisms of Lin28B action.
Our investigation into the role of LIN28B in MC development agrees with previous work implicating Lin28 as a factor that favors more primitive cellular phenotypes. The phenotype of MCs in adult mice induced to express LIN28B resembles the published phenotype of fetal liver-derived MCs. 52 In our analyses, hematopoiesis in LIN28B-induced fetal liver showed the same bias toward MEPs at the expense of granulocyte-macrophage precursors (data not shown), indicating that upregulation of LIN28B impacts myelopoiesis even when Lin28b expression is already high.
Previous studies have reported differences in the ability of ectopic Lin28 to induce hematologic malignancy. 43, 44, 46 In our system, we did not observe malignancy in transplant recipients of mouse iLIN28B BM, even after months of LIN28B induction. Our finding that Hmga2 expression was not increased in mouse BMMCs induced to express LIN28B may explain these discrepancies, suggesting that mechanisms downstream of let-7 can abrogate the oncogenic effects of Lin28b on Hmga2 in some settings. Nonetheless, LIN28B upregulation has been described in human hematologic malignancies such as blast crisis CML, 29 and we describe here the marked upregulation of both LIN28B and HMGA2 in abnormal MCs from patients with SM and MCL. It is interesting to note that this upregulation occurred regardless of clinical subtype or of c-kit mutation status, suggesting that LIN28B may complement c-kit in the pathogenesis of MC disease. The induction of LIN28B expression in SM is intriguing and warrants further investigation, ideally on untreated primary patient samples, to determine the role of LIN28 in MC disorders and its interaction with the c-Kit mutation. Thus, our findings implicating Lin28b as a novel regulator of MC fate and function highlight the need for more extensive study of this protein in human MC disease.
